No connection

Search Results

CLVT

BEARISH
$2.45 Live
Clarivate Plc · NYSE
Target $3.61 (+47.5%)
$1.66 52W Range $4.77

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 25, 2026
Market cap
$1.57B
P/E
N/A
ROE
-4.0%
Profit margin
-8.2%
Debt/Equity
0.93
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
CLVT exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a complete lack of positive technical momentum. While valuation metrics like Price/Book (0.32) and Forward P/E (3.13) suggest a deep-value opportunity, these are offset by negative revenue growth (-6.90%) and a critical liquidity position with a current ratio of 0.83. The stock is in a long-term collapse, losing over 90% of its value over five years, suggesting a 'value trap' scenario where low multiples reflect fundamental deterioration rather than market inefficiency.

Key Strengths

Strong gross margins at 66.05%
Consistent track record of beating quarterly earnings estimates
Extremely low Price-to-Book ratio (0.32)
Positive operating margin (9.40%) despite negative net profit
Low PEG ratio (0.18) based on forward projections

Key Risks

Weak financial health indicated by Piotroski F-Score of 2/9
Negative revenue growth (YoY -6.90% and Q/Q -6.94%)
Liquidity risk with Current Ratio (0.83) and Quick Ratio (0.73) below 1.0
Severe long-term price depreciation (5Y Change: -90.7%)
Negative net profit margin (-8.19%) and negative ROE (-4.03%)
AI Fair Value Estimate
Based on comprehensive analysis
$3.0
+22.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
28
Weak
Value
85
Future
20
Past
10
Health
25
Dividend
0
AI Verdict
Value Trap
Key drivers: Piotroski F-Score 2/9, Negative Revenue Growth, Severe 5Y Price Decline, Liquidity Shortfall
Confidence
90%
Value
85/100

Trades at a massive discount to book value and forward earnings.

Positives
  • P/B of 0.32
  • Forward P/E of 3.13
  • P/S of 0.64
Watchpoints
  • Low multiples likely reflect declining fundamentals
Future
20/100

Growth metrics are trending downward across both revenue and earnings.

Positives
  • Consistent EPS beats
Watchpoints
  • Negative YoY revenue growth
  • Negative YoY EPS growth
Past
10/100

Catastrophic long-term price performance.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -90.7%
  • 1Y Change: -30.0%
Health
25/100

Deterministic health scores indicate high risk and poor operational efficiency.

Positives
  • Manageable Debt/Equity (0.93)
Watchpoints
  • Piotroski F-Score 2/9
  • Current Ratio < 1.0
Dividend
0/100

Non-dividend paying stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.45
Analyst Target
$3.61
Upside/Downside
+47.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for CLVT and closest competitors.

Updated 2026-04-24
CLV
Clarivate Plc
Primary
5Y
-90.7%
3Y
-71.8%
1Y
-30.0%
6M
-32.9%
1M
-1.2%
1W
-8.6%
KAR
Karooooo Ltd.
Peer
5Y
+96.3%
3Y
+140.8%
1Y
+28.8%
6M
-1.5%
1M
+7.4%
1W
+2.1%
WLT
Wealthfront Corporation
Peer
5Y
-24.7%
3Y
-24.7%
1Y
-24.7%
6M
-24.7%
1M
+26.0%
1W
-3.8%
GTM
ZoomInfo Technologies Inc.
Peer
5Y
-89.0%
3Y
-77.3%
1Y
-33.3%
6M
-47.5%
1M
-16.9%
1W
-10.0%
AEH
Aehr Test Systems, Inc.
Peer
5Y
+2011.7%
3Y
+89.5%
1Y
+622.4%
6M
+64.8%
1M
+46.5%
1W
+73.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
3.13
PEG Ratio
0.18
P/B Ratio
0.32
P/S Ratio
0.64
EV/Revenue
2.33
EV/EBITDA
6.17
Market Cap
$1.57B

Profitability

Profit margins and return metrics

Profit Margin -8.19%
Operating Margin 9.4%
Gross Margin 66.05%
ROE -4.03%
ROA 0.95%

Growth

Revenue and earnings growth rates

Revenue Growth -6.9%
Earnings Growth N/A
Q/Q Revenue Growth -6.94%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.93
Moderate
Current Ratio
0.83
Weak
Quick Ratio
0.73
Poor
Cash/Share
$0.5

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.6B
Gross Margin
66.8%
Op. Margin
9.4%
Net Margin
0.5%
Total Assets
$11.1B
Liabilities
$6.2B
Equity
$4.8B
Debt/Equity
1.29x
Operating CF
$0.2B
CapEx
$-0.1B
Free Cash Flow
$0.1B
FCF Yield
56%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-29
$N/A
2026-02-24
$0.2
+22.2% surprise
2025-10-29
$0.18
+15.1% surprise
2025-07-30
$0.18
+3.4% surprise

Technology Sector Comparison

Comparing CLVT against 528 companies in the Technology sector (46 bullish, 175 neutral, 307 bearish)
Return on Equity (ROE)
-4.03%
This Stock
vs
-36.43%
Sector Avg
-88.9% (Below Avg)
Profit Margin
-8.19%
This Stock
vs
-12.81%
Sector Avg
-36.0% (Weaker)
Debt to Equity
0.93
This Stock
vs
0.71
Sector Avg
+31.2% (Higher)
Revenue Growth
-6.9%
This Stock
vs
4697.82%
Sector Avg
-100.1% (Slower)
Current Ratio
0.83
This Stock
vs
3.69
Sector Avg
-77.4% (Weaker)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-01

CLVT filed a Definitive Proxy Statement on April 1, 2026, providing shareholders with necessary information to vote on corporate matters at the upcoming annual meeting.

8-K
8-K
2026-03-26
8-K
8-K
2026-02-24

ClearView Healthcare Trust filed a current report on February 24, 2026, likely announcing its fourth quarter and full-year financial results.

10-K
10-K
2026-02-24

CLVT filed its annual 10-K on February 24, 2026, which includes detailed disclosures regarding its business operations, risk factors, and financial condition. The filing provides management's discussion and analysis of results, though specific financial metrics and risk details were not provided in the available excerpts.

8-K
8-K
2026-02-03

CLVT filed an 8-K on February 3, 2026, likely to report its fourth quarter and full-year financial results.

8-K
8-K
2026-02-02

ClearView Healthcare Trust filed an 8-K on February 2, 2026, likely to report its fourth-quarter and full-year financial results.

10-Q
10-Q
2025-10-29

CLVT filed its quarterly 10-Q report on October 29, 2025. The provided excerpts contain no specific financial highlights or risk details, referring instead to the 2024 annual report and Note 1 for accounting policies and operational summaries.

8-K
8-K
2025-10-29

ClearView Healthcare Trust filed an 8-K on October 29, 2025, likely to announce its third-quarter financial results.

8-K
FORM 8-K
2025-08-05

ClearView Healthcare Trust filed an 8-K on August 5, 2025, likely to announce its second-quarter financial results.

8-K
FORM 8-K
2025-07-30
8-K
8-K
2025-07-30

ClearView Healthcare Trust likely reported its second-quarter financial results in this 8-K filing.

10-Q
10-Q
2025-07-30
8-K
FORM 8-K
2025-07-22
8-K
FORM 8-K
2025-06-02
8-K
FORM 8-K
2025-05-19
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
7 analysts
Citigroup
2026-03-04
Maintains
Neutral Neutral
Barclays
2026-02-25
Maintains
Underweight Underweight
RBC Capital
2026-02-25
Maintains
Sector Perform Sector Perform
Goldman Sachs
2026-01-08
down
Buy Neutral
Morgan Stanley
2025-12-17
down
Equal-Weight Underweight

Past News Coverage

Recent headlines mentioning CLVT from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile